"Sickle cell disease is a devasting disorder that affects approximately 100,000 people in the U.S., leading to anemia, severe pain, stroke and even early death. Receiving orphan drug designation from ...

The American Society of Hematology (ASH) and the International Society on Thrombosis and Hemostasis (ISTH) released new and updated clinical practice guidelines for the treatment of pediatric ...

The American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) released new and updated clinical practice guidelines for the treatment of pediatric ...

Thanks to rapid drug development and expanding clinical research, patients now have access to more personalized treatment options than ever before. But for healthcare providers—doctors ...

An improvement in the Myelofibrosis Symptom Assessment Form total ... unrelated to treatment; the most common adverse events were thrombocytopenia and diarrhea. Just before ASH 2024, Keros ...

Cite this: Progress in Paroxysmal Nocturnal Hemoglobinuria Treatment: The Impact of New Data From ASH 2024 - Medscape - Jan 02, 2025. Professor of Clinical Medicine, Jane Anne Nohl Division ...

Dr Lindsay Rein comments on significant advancements in CML treatment presented at ASH 2024, particularly the ... option will have a major impact on clinical care because clinicians now have ...

Objective response rate (ORR) of 94% and a complete response (CR) rate of 71% demonstrated after IMPT-314 treatment ... clinical studies. The data are being presented today at the 2024 ASH Annual ...

Additionally, the data from our ESCAPE nongenotoxic conditioning program - to be presented on Sunday - highlight our commitment to expanding access to treatment ... clinical trial designs and ...

--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying ... th American Society of Hematology (ASH) Annual Meeting and Exposition ...

Arcellx to Present Clinical ... (ASH) Annual Meeting and Exposition taking place December 7-10, 2024, in San Diego, California. Additionally, an abstract (#6962) describing the treatment patterns ...

The oral presentation will describe clinical data from a completed Phase 1b study of ELA026 for the treatment of secondary ... The abstract is published on the ASH website. "We are delighted ...